Search results

Body

Showing 41-50 of 255 results
The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Semaglutide improves symptoms in both men and women who present with heart failure. When it comes to weight loss, however, the drug appears to benefit women much more than men.
The new, co-developed AFib program delivers holistic care that magnifies specialty providers’ ability to see more patients and improve their quality of life.

KANSAS CITY, Mo. (May 5, 2014) — Saint Luke’s Mid America Heart Institute interventional cardiologists are on the forefront of perfecting new minimally invasive approaches to treat chronic

New scientific paper proposes SGLT inhibitors as a therapy to slow aging at the cellular level and improve longevity.
Saint Luke’s program becomes the 23rd institution in the U.S. to perform 1,000 heart transplants.
Peripheral Artery Disease (PAD) is a disease that impacts 3 million Americans every year.
Dr. Mikhail Kosiborod presented findings of the DARE-19 Trial at the ACC Scientific Session.

Saint Luke’s is a world leader in treating chronic total occlusions (CTOs), or arteries that are completely blocked by plaque buildup.

Dr. John Spertus talks to the Kansas City Business Journal about his new groundbreaking ISCHEMIA study and how precision medicine will change the business of cardiology.